Landmark Bio Appoints Gregg Nyberg, Ph.D., as Chief Technology Officer and Michael Covington as Chief Quality and Regulatory Officer
Newest members of Landmark Bio’s executive team bring decades of industry leadership and expertise in drug development and biomanufacturing
Nyberg and Covington will help accelerate development and industrialization of novelmodalities through leading-edge science and technologies, public-private collaborations
WATERTOWN, Mass., October 19, 2021 – Landmark Bio™, a collective endeavor launched byleaders from academia, the life sciences industry, and world-renowned research hospitals toaccelerate development and industrialization of novel therapeutics, today announced theappointment of two new leaders to its executive team: Gregg Nyberg, Ph.D., as chieftechnology officer (CTO) and Michael Covington as chief quality and regulatory officer (CQRO).
Ran Zheng, chief executive officer of Landmark Bio stated, “Gregg’s work has transformedmillions of lives, and Landmark Bio is honored to welcome him as our chief technology officer. He brings a long track record of success leading technical operations and process developmentat companies like Merck and Amgen. Gregg’s expertise will improve our ability to leverage andbuild emerging technologies for cell and gene therapies, mRNA, and other novel modalities toultimately benefit patients.”
Ms. Zheng further commented, “Michael is a respected industry leader known for building highperformingteams from the ground up. His expertise in establishing regulatory practices and strategies will ensure Landmark Bio can enable our partners move from concept to commercialization with full compliance, consistent processes, and the highest quality. Bringing Michael and Gregg to the Landmark Bio executive team will further enable us to deliver on ourmission to translate cutting-edge research into groundbreaking next-generation therapiesthrough advanced biomanufacturing and technology innovation.”
Gregg Nyberg, Ph.D., Named Chief Technology Officer
Dr. Nyberg brings more than 20 years’ biopharmaceutical industry experience to his new role at Landmark Bio. Most recently, he was associate vice president at Merck, where he led thecompany’s biologics process development and clinical manufacturing organizations. He alsospent nearly 15 years in positions of increasing responsibility at Amgen including key leadershiproles in process development and cell sciences and technology.
“Fostering collaboration between private and public groups – with the goal of making anindelible impact on society – is at the heart of what Landmark Bio does,” said Dr. Nyberg. “Ilook forward to bringing my technical expertise to this organization and helping patientsdesperately in need of treatment options.”
Dr. Nyberg earned a Ph.D. in chemical engineering from the Massachusetts Institute of Technology (MIT) and a B.S. in chemical engineering and petroleum refining from the ColoradoSchool of Mines.
Michael Covington Named CQRO
Mr. Covington brings three decades of biotechnology, cellular, and gene therapy experience inareas including regulatory affairs, regulatory compliance, quality, validation, andmanufacturing. He has demonstrated success in supporting innovative therapies includingadeno-associated vector (AAV) gene therapies, autologous genetically modified hematopoieticstem and progenitor cell therapies for rare diseases, autologous genetically modified T cellimmunotherapies, and other autologous immunotherapies, as well as recombinant proteintherapeutics.
“There has never been a more exciting and promising time for biotechnology, and Landmark Bio was founded to utilize today’s emerging science and technologies to help developtreatments for patients suffering from life-threatening diseases,” said Mr. Covington. “We aimto create world-class end-to-end CMC development capabilities for companies working onnovel modalities – such as cell, gene, and mRNA therapies – that harness the power of thehuman body to heal itself.”
Most recently, Mr. Covington was the vice president of Regulatory Chemistry, Manufacturing,and Controls (CMC) for Novartis Gene Therapies. Prior to Novartis, he was vice president ofRegulatory CMC for Orchard Therapeutics, and held leadership positions with Juno Therapeutics, Dendreon, and Amgen. He earned a B.A. in biology, cellular, and molecularbiology from the University of Missouri-Columbia.
About Landmark Bio™
Landmark Bio PBLLC, a Public Benefit Limited Liability Company, or PBLLC, is a collectiveendeavor launched by leaders from academia, the life sciences industry, and world-renownedresearch hospitals to accelerate the development and industrialization of novel therapeutics. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established toremove barriers in drug development, create accessible capacity, expertise, and solutions, andoffer a collaboration platform to advance manufacturing technologies for the new generationof medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities,Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center. For more information, visit https://landmarkbio.com.